Certificate in Cancer Immunotherapy

Purpose

The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches.

Target Audiences

The primary target audience for the program is treating physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate will also be available to practicing, licensed NPs, PAs, and PharmDs. The courses will be available to those who have advanced degrees but are not practicing clinicians, but they will not be eligible to earn the certificate.

Scope

The scope of the program is the fundamental body of cancer immunotherapeutic work, including:
  • Basic immunology concepts
  • Basic cancer immunotherapy concepts
  • Immune checkpoint blockade
  • Managing immune checkpoint inhibitor adverse events
  • Other approaches (cytokines, small molecules, vaccines, T cell engagers)
  • Oncolytic viruses and intralesional therapy
  • CAR T cell and cellular therapy
  • Combinations including immunotherapies
  • Implementing cancer immunotherapy in clinical practice

CP2_-_Copy.png
CP1.png

Certificate Task Force

CHAIR

Robert L. Ferris, MD, PhD
UPMC Hillman Cancer Center


Members

Leisha Emens, MD, PhD — UPMC Hillman Cancer Center
Umar Farooq, MD — University of Iowa
Silvia Formenti, MD — Weill Cornell Medicine
Sigrun Hallmeyer, MD — Advocate Medical Group
Howard Kaufman, MD, FACS — Replimune Group Inc.
Jose Lutzky, MD, FACP — Mount Sinai Comprehensive Cancer Center
George Weiner, MD — University of Iowa

More information on the Certificate in Cancer Immunotherapy coming soon.